Juvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Juvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2024 report and make more profitable business decisions.
Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease, an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision; dark, empty spots in the center of vision; and difficulty reading or performing detail work. Risk factors include arteriosclerosis, hypercholesterolemia, smoking, and hypertension.
The Juvenile Macular Degeneration (Stargardt Disease) drugs in development market research report provide comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Juvenile Macular Degeneration (Stargardt Disease) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 33 molecules, with 32 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Juvenile Macular Degeneration (Stargardt Disease) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Juvenile Macular Degeneration (Stargardt Disease) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Juvenile Macular Degeneration (Stargardt Disease) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
4P-Pharma SASAAVantgarde Bio Srl
Abeona Therapeutics Inc
Alkeus Pharmaceuticals Inc
Ascidian Therapeutics Inc
Astellas Pharma Inc
Beam Therapeutics Inc
Beijing Chinagene Tech Co Ltd
Belite Bio Inc
Biophytis SA
Cardax Inc
Carmine Therapeutics Inc
Chengdu Genevector Biotechnology Co Ltd
Curative Biotechnology Inc
Eudora
Fera Pharmaceuticals LLC
Fondazione Telethon
Generation Bio Co
Grupo Ferrer Internacional SA
Insmed Inc
IVERIC bio Inc
KALA BIO Inc
Kiora Pharmaceuticals Inc
Kubota Vision Inc
Lysoclear Inc
Nanoscope Therapeutics Inc
Ocugen Inc
Ray Therapeutics Inc
ReVision Therapeutics Inc
Spark Therapeutics Inc
Splice Bio SL
Visgenx Inc
Table of Contents
Table
Figures
Frequently asked questions